Friend or foe? Multi-omics analysis unravels the complex identity of key pyroptosis factor CASP9 in clear cell renal cell carcinoma

Abstract

Objective

Pyroptosis, an important form of cell death, remains to be explored for its significance in renal cell carcinoma.

Methods

We conducted a Summary-data-based Mendelian Randomization (SMR) analysis to investigate the association between pyrogenic gene-related SNPs and renal cell carcinoma outcomes, identified core genes with significant associations, and then performed transcriptomic profiling analysis of renal clear cell carcinoma using TCGA data to assess diagnostic and prognostic potential. Subsequently, we explored the functional mediation of core genes through enrichment analysis and GSEA, and analyzed immune function using Cibersort and ssGSEA. We then presented the expression patterns of core genes using single-cell data, and finally analyzed the differences in chemotherapy sensitivity between high- and low-expression groups of core genes using oncoPredict, and validated the potential for targeting core genes with molecular drugs.

Results

Through SMR and MR, we identified CASP9 as a key factor in pyroptosis-related processes in renal cell carcinoma, acting as a protective factor for renal cell carcinoma outcomes and demonstrating excellent diagnostic potential. Survival analysis revealed that high CASP9 expression in early-stage renal cell carcinoma was associated with better prognosis, whereas the opposite was true in advanced-stage renal cell carcinoma. Functional enrichment analysis indicated that CASP9 may mediate multiple pathways, including epithelial-mesenchymal transition. Immune infiltration analysis highlighted a strong correlation between CASP9 expression and natural killer cell abundance. Finally, we analyzed differences in chemotherapy sensitivity between high- and low-CASP9 expression groups and identified potential drugs for molecular docking validation.

Conclusion

CASP9 can serve as a potential target for renal clear cell carcinoma, with potential for guiding diagnosis, prognosis, and chemotherapy selection.

Keywords

Pyroptosis / CASP9 / Mendelian randomization / SMR / Precision oncology

References

[1] SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-49

[2] Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(1):71–90.

[3] HuangX, YangD, ZhuJ, WangN, LiuL, NieF. Application value of contrast-enhanced ultrasound in the preoperative evaluation of renal cell carcinoma histological classification and RENAL score. Quant Imaging Med Surg, 2024, 14(12): 9444-9458.

[4] HirataH, HinodaY, UenoK, NakajimaK, IshiiN, DahiyaR. Microrna-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis, 2012, 33(3): 501-508.

[5] QuinnAE, BellSD, MarrahAJ, WakefieldMR, FangY. The Current State of the Diagnoses and Treatments for Clear Cell Renal Cell Carcinoma. Cancers (Basel), 2024, 16234034.

[6] FangY, TianS, PanY, LiW, WangQ, TangY, et al.. Pyroptosis: a new frontier in cancer. Biomed Pharmacother, 2020, 121. 109595

[7] ShiJ, GaoW, ShaoF. Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death. Trends Biochem Sci, 2017, 42(4): 245-254.

[8] RuanJ, WangS, WangJ. Mechanism and regulation of pyroptosis-mediated in cancer cell death. Chem Biol Interact, 2020, 25323. 109052

[9] ErkesDA, CaiW, SanchezIM, PurwinTJ, RogersC, FieldCO, et al.. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov, 2020, 10(2): 254-69.

[10] KarkiR, KannegantiTD. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat Rev Cancer, 2019, 19(4): 197-214.

[11] YeL, LongC, XuB, et al.. Multi-omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study. Mol Med, 2025, 315.

[12] SunD, WangJ, HanY, DongX, GeJ, ZhengR, ShiX, WangB, LiZ, RenP, SunL, YanY, ZhangP, ZhangF, LiT, WangC. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res, 2021, 49(D1): D1420-D1430.

[13] BorcherdingN, VishwakarmaA, VoigtAP, BellizziA, KaplanJ, NeppleK, SalemAK, JenkinsRW, ZakhariaY, ZhangW. Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. Commun Biol, 2021, 41122.

[14] WuTD, MadireddiS, de AlmeidaPE, BanchereauR, ChenYJ, ChitreAS, ChiangEY, IftikharH, O'GormanWE, Au-YeungA, TakahashiC, GoldsteinLD, PoonC, KeerthivasanS, de Almeida NagataDE, DuX, LeeHM, BantaKL, MariathasanS, Das ThakurM, HuseniMA, BallingerM, EstayI, CaplaziP, ModrusanZ, DelamarreL, MellmanI, BourgonR, GroganJL. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature, 2020, 579(7798): 274-278.

[15] NewmanAM, LiuCL, GreenMR, GentlesAJ, FengW, XuY, HoangCD, DiehnM, AlizadehAA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015, 12(5): 453-457.

[16] ChiC, YeY, ChenB, HuangH. Bipartite graph-based approach for clustering of cell lines by gene expression-drug response associations. Bioinformatics, 2021, 37(17): 2617-2626.

[17] Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41(Database issue):D955–61.

[18] ZengJ, ZhuP, TangY, et al.. Identification of pyroptosis-related subtypes and comprehensive analysis of characteristics of the tumor microenvironment infiltration in clear cell renal cell carcinoma. Sci Rep, 2023, 1316055.

[19] HuangC, LiJ, WuR, LiY, ZhangC. Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Mol Cancer, 2025, 241. 131

[20] LiuZ, LiY, ZhuY, LiN, LiW, ShangC, SongG, LiS, CongJ, LiT, XiuZ, LuJ, GeC, YangX, LiY, SunL, LiX, JinN. Apoptin induces pyroptosis of colorectal cancer cells via the GSDME-dependent pathway. Int J Biol Sci, 2022, 18(2): 717-730.

[21] Gałuszka-BulagaA, TkaczK, WęglarczykK, SiedlarM, BaranJ. Air pollution induces pyroptosis of human monocytes through activation of inflammasomes and Caspase-3-dependent pathways. J Inflamm (Lond), 2023, 20126.

[22] QianX, LiuY, ChenW, ZhengS, LuY, QiuP, KeX, TangH, ZhangX. Paris saponin VII induces Caspase-3/GSDME-dependent pyroptosis in pancreatic ductal adenocarcinoma cells by activating ROS/Bax signaling. Chin Herb Med, 2024, 17(1): 94-107

[23] ChenKW, DemarcoB, HeiligR, ShkarinaK, BoettcherA, FaradyCJ, et al.. Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly. EMBO J, 2019, 3810. e101638

[24] KangBS, LeeK, LeeHJ, HanHJ, KimG, KimD, LeeEB. Dose-dependent apoptotic effect of Woodfordia fruticosa on hepatocellular carcinoma (HepG2) cells by upregulating bax and caspase-9. 3 Biotech, 2025, 157. 220

[25] LiP, ZhouL, ZhaoT, LiuX, ZhangP, LiuY, ZhengX, LiQ. Caspase-9: structure, mechanisms and clinical application. Oncotarget, 2017, 8(14): 23996-24008. Apr 4;

[26] KimB, SrivastavaSK, KimSH. Caspase-9 as a therapeutic target for treating cancer. Expert Opin Ther Targets, 2015, 19(1): 113-127.

[27] HakimF, KazemiraadC, Akbari-BirganiS, AbdollahpourD, MohammadiS. Caspase-9-mediated cleavage of vimentin attenuates the aggressiveness of leukemic NB4 cells. Mol Cell Biochem, 2023, 478(11): 2435-2444.

[28] HanC, LiuZ, ZhangY, ShenA, DongC, ZhangA, MooreC, RenZ, LuC, CaoX, ZhangCL, QiaoJ, FuYX. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nat Immunol, 2020, 21(5): 546-554.

[29] Huang Z, Zhang Z, Zhou C, Liu L, Huang C. Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (2020). 2022;3(2):e144.

[30] HaoY, BakerD, Ten DijkeP. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci, 2019, 20112767.

[31] LandoltL, EikremØ, StraussP, SchererA, LovettDH, BeislandC, FinneK, OsmanT, IbrahimMM, GausdalG, AhmedL, LorensJB, ThieryJP, TanTZ, SekulicM, MartiHP. Clear cell renal cell carcinoma is linked to epithelial-to-mesenchymal transition and to fibrosis. Physiol Rep, 2017, 511. e13305

[32] SugimotoM, KohashiK, ItsumiM, ShiotaM, AbeT, YamadaY, KuroiwaK, NaitoS, OdaY. Epithelial to mesenchymal transition in clear cell renal cell carcinoma with rhabdoid features. Pathobiology, 2016, 83(6): 277-286.

[33] XuH, XuWH, RenF, WangJ, WangHK, CaoDL, ShiGH, QuYY, ZhangHL, YeDW. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma. Aging (Albany NY), 2020, 12(1): 866-883.

[34] GasinskaA, JaszczynskiJ, AdamczykA, Janecka-WidłaA, WilkW, CichockaA, et al.. Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma. Folia Histochem Cytobiol, 2018, 56(4): 195-206.

[35] IlutaS, NistorM, BuruianaS, DimaD. Wnt Signaling Pathway in Tumor Biology. Genes (Basel), 2024, 15121597.

[36] TakebeN, MieleL, HarrisPJ, JeongW, BandoH, KahnM, YangSX, IvySP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol, 2015, 12(8): 445-464.

[37] GeisslerK, FornaraP, LautenschlägerC, HolzhausenHJ, SeligerB, RiemannD. Immune signature of tumor infiltrating immune cells in renal cancer. Oncoimmunology, 2015, 41. e985082

[38] StörkelS, KeymerR, SteinbachF, ThoenesW. Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog Clin Biol Res, 1992, 378: 217-223

[39] MorelliMB, AmantiniC, SantoniM, SorianiA, NabissiM, CardinaliC, SantoniA, SantoniG. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells. Oncotarget, 2015, 6(34): 36245-36259.

[40] HungK, HayashiR, Lafond-WalkerA, LowensteinC, PardollD, LevitskyH. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med, 1998, 188(12): 2357-2368.

[41] ChenJ, GongC, MaoH, LiZ, FangZ, ChenQ, LinM, JiangX, HuY, WangW, ZhangX, ChenX, LiH. E2f1/SP3/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells. Int J Oncol, 2018, 53(2): 567-578

[42] ZhangQ, QinJ, ZhongL, GongL, ZhangB, ZhangY, GaoWQ. CCL5-Mediated Th2 Immune Polarization Promotes Metastasis in Luminal Breast Cancer. Cancer Res, 2015, 75(20): 4312-4321.

[43] SchreiberS, HammersCM, KaaschAJ, SchravenB, DudeckA, KahlfussS. Metabolic Interdependency of Th2 Cell-Mediated Type 2 Immunity and the Tumor Microenvironment. Front Immunol, 2021, 3112. 632581

[44] YinS, JinW, QiuY, FuL, WangT, YuH. Solamargine induces hepatocellular carcinoma cell apoptosis and autophagy via inhibiting LIF/miR-192-5p/CYR61/Akt signaling pathways and eliciting immunostimulatory tumor microenvironment. J Hematol Oncol, 2022, 15132.

[45] FuR, WangX, HuY, DuH, DongB, AoS, ZhangL, SunZ, ZhangL, LvG, JiJ. Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway. Int J Oncol, 2019, 54(5): 1545-1554

[46] ZhangL, ChenJ, ChenY, ZouD, PuY, WeiM, et al.. Corrigendum to: Alantolactone inhibits melanoma cell culture viability and migration and promotes apoptosis by inhibiting Wnt/β-catenin signaling. Anticancer Agents Med Chem, 2025, 25(12): 883-4.

[47] HuangY, XiangP, ChenY, PanQ, YuanK. Alantolactone facilitates ferroptosis in non-small cell lung cancer through promoting FTH1 ubiquitination and degradation. Chem Biol Drug Des, 2024, 1042. e14560

RIGHTS & PERMISSIONS

The Author(s)